Actively Recruiting
Phase 3 Study Comparing ESG401 to Chemotherapy as First Treatment for Unresectable Recurrent or Metastatic Triple-Negative Breast Cancer
Led by Qilu Pharmaceutical Co., Ltd. · Updated on 2025-09-23
504
Participants Needed
1
Research Sites
56 weeks
Total Duration
AI-Summary
What This Trial Is About
Researchers are evaluating ESG401 as a first treatment option for patients with unresectable recurrent or metastatic triple-negative breast cancer, a type of breast cancer that lacks certain receptors. This Phase 3, randomized, open-label, multicenter study compares ESG401 to chemotherapy chosen by the investigator. The goal is to assess the effectiveness and safety of ESG401 in this patient group. Participants will receive either ESG401 through intravenous infusions on days 1, 8, and 15 of each 28-day cycle or Investigators Choice Chemotherapy. The chemotherapy options depend on prior treatment and include paclitaxel, nab-paclitaxel, capecitabine, eribulin, or carboplatin based on specific criteria such as prior taxane use and BRCA12 mutation status. During the study, participants will be monitored for tumor progression and survival outcomes for up to approximately 28 to 41 months after randomization. Assessments include scans to evaluate tumor response, quality of life questionnaires, and safety monitoring for adverse events. Researchers will also measure how the drug is processed in the body and immune responses over the treatment period.
CONDITIONS
Brief Title
A Phase III Study of ESG401 for Unresectable Recurrent or Metastatic Triple-Negative Breast Cancer
Research Team
X
Xiaoyan Xing, PhD
F
Fei Ma, PhD
Not the Right Trial for You?
Explore thousands of other clinical trials that might be a better match.
Sign up to get personalized trial recommendations delivered to your inbox.
Already have an account? Log in here